Study | Outcome | Subgroup | 3 months postinjection | 6 months postinjection | 12 months postinjection |
---|---|---|---|---|---|
Vaquerizo et al36 | Pain | Percentage of patients having a 50% decrease in the WOMAC pain subscale | + | + | |
Function | Percentage of patients having a 50% decrease in the WOMAC physical function subscale | + | + | ||
Percentage of patients having a 50% decrease in the Lequesne index | + | + | |||
WOMAC total score | + | + | |||
Lequesne index | + | + | |||
Cerza et al39 | Function | WOMAC total score | + | + | |
Sánchez et al40 | Pain | Percentage of patients having a 50% decrease in the WOMAC pain subscale | + | ||
WOMAC pain subscale | − | ||||
Function | WOMAC physical function subscale | − | |||
WOMAC total score | − | ||||
Lequesne index | − | ||||
Li et al43 | Function | WOMAC total score | − | + | |
Lequesne index | − | + | |||
Spaková et al42 | Pain | NRS | + | + | |
Function | WOMAC total score | + | + | ||
Say et al41 | Pain | VAS | + | + |
+, indicates positive effect derived from the p value (p value <0.05);
−, indicates negative effect derived from the p value (p value >0.05);
NRS, numeric rating scale; VAS, visual analogue scale; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index.